The global Monoamine Oxidase Type B (MAO-BI) Inhibitors market size is predicted to grow from US$ 356 million in 2025 to US$ 452 million in 2031; it is expected to grow at a CAGR of 4.0% from 2025 to 2031.
Monoamine Oxidase Type B Inhibitors (MAO-BIs) are a class of drugs that selectively inhibit the activity of the monoamine oxidase B enzyme, which is responsible for breaking down dopamine in the brain. By preventing dopamine degradation, MAO-B inhibitors help increase dopamine levels, making them effective in the treatment of neurodegenerative disorders such as Parkinson鈥檚 disease. Common MAO-B inhibitors include selegiline, rasagiline. These drugs are often used alone in the early stages of Parkinson鈥檚 or in combination with other treatments to enhance their therapeutic effects.
United States market for Monoamine Oxidase Type B (MAO-BI) Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Monoamine Oxidase Type B (MAO-BI) Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Monoamine Oxidase Type B (MAO-BI) Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Monoamine Oxidase Type B (MAO-BI) Inhibitors players cover Fujimoto, Orion Corporation, Viatris, chiesi, Apotex, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淢onoamine Oxidase Type B (MAO-BI) Inhibitors Industry Forecast鈥� looks at past sales and reviews total world Monoamine Oxidase Type B (MAO-BI) Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Monoamine Oxidase Type B (MAO-BI) Inhibitors sales for 2025 through 2031. With Monoamine Oxidase Type B (MAO-BI) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoamine Oxidase Type B (MAO-BI) Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Monoamine Oxidase Type B (MAO-BI) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Monoamine Oxidase Type B (MAO-BI) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Monoamine Oxidase Type B (MAO-BI) Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoamine Oxidase Type B (MAO-BI) Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoamine Oxidase Type B (MAO-BI) Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Monoamine Oxidase Type B (MAO-BI) Inhibitors market by product type, application, key players and key regions and countries.
Segmentation by Type:
Selegiline
Rasagiline
Segmentation by Application:
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Fujimoto
Orion Corporation
Viatris
chiesi
Apotex
Lvye Pharma
Abbott
Kyowa Pharmaceutical
Bausch Health
Intas Pharmaceutical
Teva
Takeda Pharmaceutical
Qilu Pharma
Lundbeck A/S
Sun Pharmaceutical
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size (2020-2031)
2.1.2 Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Monoamine Oxidase Type B (MAO-BI) Inhibitors by Country/Region (2020, 2024 & 2031)
2.2 Monoamine Oxidase Type B (MAO-BI) Inhibitors Segment by Type
2.2.1 Selegiline
2.2.2 Rasagiline
2.3 Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Type
2.3.1 Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Monoamine Oxidase Type B (MAO-BI) Inhibitors Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Application
2.5.1 Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Player
3.1 Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue by Player (2020-2025)
3.1.2 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Monoamine Oxidase Type B (MAO-BI) Inhibitors by Region
4.1 Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Region (2020-2025)
4.2 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors Annual Revenue by Country/Region (2020-2025)
4.3 Americas Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size Growth (2020-2025)
4.4 APAC Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size Growth (2020-2025)
4.5 Europe Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Country (2020-2025)
5.2 Americas Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Type (2020-2025)
5.3 Americas Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Region (2020-2025)
6.2 APAC Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Type (2020-2025)
6.3 APAC Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Country (2020-2025)
7.2 Europe Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Type (2020-2025)
7.3 Europe Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Monoamine Oxidase Type B (MAO-BI) Inhibitors by Region (2020-2025)
8.2 Middle East & Africa Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Forecast
10.1 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast by Region (2026-2031)
10.1.1 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast by Region (2026-2031)
10.1.2 Americas Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.1.3 APAC Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.1.4 Europe Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.1.5 Middle East & Africa Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.2 Americas Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.2.2 Canada 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.2.3 Mexico 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.2.4 Brazil 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.3 APAC Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast by Region (2026-2031)
10.3.1 China Monoamine Oxidase Type B (MAO-BI) Inhibitors 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.3.3 Korea 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.3.4 Southeast Asia 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.3.5 India 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.3.6 Australia 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.4 Europe Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.4.2 France 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.4.3 UK 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.4.4 Italy 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.4.5 Russia 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.5 Middle East & Africa Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.5.2 South Africa 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.5.3 Israel 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.5.4 Turkey 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
10.6 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast by Type (2026-2031)
10.7 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Monoamine Oxidase Type B (MAO-BI) Inhibitors Forecast
11 Key Players Analysis
11.1 Fujimoto
11.1.1 Fujimoto Company Information
11.1.2 Fujimoto Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.1.3 Fujimoto Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Fujimoto Main Business Overview
11.1.5 Fujimoto Latest Developments
11.2 Orion Corporation
11.2.1 Orion Corporation Company Information
11.2.2 Orion Corporation Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.2.3 Orion Corporation Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Orion Corporation Main Business Overview
11.2.5 Orion Corporation Latest Developments
11.3 Viatris
11.3.1 Viatris Company Information
11.3.2 Viatris Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.3.3 Viatris Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Viatris Main Business Overview
11.3.5 Viatris Latest Developments
11.4 chiesi
11.4.1 chiesi Company Information
11.4.2 chiesi Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.4.3 chiesi Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 chiesi Main Business Overview
11.4.5 chiesi Latest Developments
11.5 Apotex
11.5.1 Apotex Company Information
11.5.2 Apotex Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.5.3 Apotex Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Apotex Main Business Overview
11.5.5 Apotex Latest Developments
11.6 Lvye Pharma
11.6.1 Lvye Pharma Company Information
11.6.2 Lvye Pharma Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.6.3 Lvye Pharma Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Lvye Pharma Main Business Overview
11.6.5 Lvye Pharma Latest Developments
11.7 Abbott
11.7.1 Abbott Company Information
11.7.2 Abbott Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.7.3 Abbott Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Abbott Main Business Overview
11.7.5 Abbott Latest Developments
11.8 Kyowa Pharmaceutical
11.8.1 Kyowa Pharmaceutical Company Information
11.8.2 Kyowa Pharmaceutical Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.8.3 Kyowa Pharmaceutical Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Kyowa Pharmaceutical Main Business Overview
11.8.5 Kyowa Pharmaceutical Latest Developments
11.9 Bausch Health
11.9.1 Bausch Health Company Information
11.9.2 Bausch Health Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.9.3 Bausch Health Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Bausch Health Main Business Overview
11.9.5 Bausch Health Latest Developments
11.10 Intas Pharmaceutical
11.10.1 Intas Pharmaceutical Company Information
11.10.2 Intas Pharmaceutical Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.10.3 Intas Pharmaceutical Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Intas Pharmaceutical Main Business Overview
11.10.5 Intas Pharmaceutical Latest Developments
11.11 Teva
11.11.1 Teva Company Information
11.11.2 Teva Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.11.3 Teva Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Teva Main Business Overview
11.11.5 Teva Latest Developments
11.12 Takeda Pharmaceutical
11.12.1 Takeda Pharmaceutical Company Information
11.12.2 Takeda Pharmaceutical Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.12.3 Takeda Pharmaceutical Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Takeda Pharmaceutical Main Business Overview
11.12.5 Takeda Pharmaceutical Latest Developments
11.13 Qilu Pharma
11.13.1 Qilu Pharma Company Information
11.13.2 Qilu Pharma Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.13.3 Qilu Pharma Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Qilu Pharma Main Business Overview
11.13.5 Qilu Pharma Latest Developments
11.14 Lundbeck A/S
11.14.1 Lundbeck A/S Company Information
11.14.2 Lundbeck A/S Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.14.3 Lundbeck A/S Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Lundbeck A/S Main Business Overview
11.14.5 Lundbeck A/S Latest Developments
11.15 Sun Pharmaceutical
11.15.1 Sun Pharmaceutical Company Information
11.15.2 Sun Pharmaceutical Monoamine Oxidase Type B (MAO-BI) Inhibitors Product Offered
11.15.3 Sun Pharmaceutical Monoamine Oxidase Type B (MAO-BI) Inhibitors Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Sun Pharmaceutical Main Business Overview
11.15.5 Sun Pharmaceutical Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
